In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SACATM meeting

This article was originally published in The Rose Sheet

Executive Summary

The Peer Review Report, "The Use of In Vitro Basal Cytotoxicity Test Methods for Estimating Starting Doses for Acute Oral Systemic Toxicity Testing," will be reviewed and discussed during the Scientific Advisory Committee on Alternative Toxicological Methods teleconference taking place Aug. 3 from 1 p.m. to 4 p.m., committee announces. Panel Report includes section that addresses the "rationale for the use of in vitro neutral red uptake cytotoxicity test methods to predict starting doses for in vivo acute oral systemic toxicity testing" and a section on the accuracy of the 3T3 and NHK NRU test methods. During a May 23 meeting of the Interagency Coordinating Committee on the Validation of Alternative Methods, a scientific peer review panel concluded the 3T3 and NHK methods are sufficient for use in a weight-of-evidence approach to determine the starting dose for acute oral in vivo toxicity testing (1"The Rose Sheet" May 29, 2006, p. 8)...

You may also be interested in...



ICCVAM Peer Review Meeting Evaluates Two In Vitro Cytotoxicity Tests

Two in vitro cytotoxicity test methods are sufficient for use in a weight-of-evidence approach to determine the starting dose for acute oral in vivo toxicity testing, a scientific peer review panel concluded by consensus during a meeting of the Interagency Coordinating Committee on the Validation of Alternative Methods in Bethesda, Md. May 23

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014065

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel